Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05207865 · ClinicalTrials.gov registry record · Phase 4
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 441
- Enrollment target
NCT05207865 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 441 participants.
The verdict
NCT05207865, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 441 participants
- Enrollment target
Study Summary
The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
Interventions
- DRUG Rimegepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 441 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2024-07-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05207865
The ClinicalTrials.gov registry entry for NCT05207865 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 441 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rimegepant is the first listed.
NCT05207865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05207865 about?
NCT05207865 is a clinical study titled "Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention". The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
What is the current status of trial NCT05207865?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 441 participants. The study started on 2022-03-15. Estimated completion is 2024-07-02.
What interventions are being tested in trial NCT05207865?
The interventions under investigation include: Rimegepant (DRUG).
Who is sponsoring clinical trial NCT05207865?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.